References
- Bastain W., Boyce M. J., Stafford P. B., Clarke D. A., Marlow H. F. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. European Journal of Clinical Pharamcology 1988; 34: 469–473
- Black S. C., Chi L., Mu D.-X., Lucchesi B. R. The antifibrillatory effect of UK-68 798, a class III antiarrhythmic agent. Journal of Pharmacology and Experimental Therapeutics 1991; 258: 41–423
- Cross P. E., Arrowsmith J. E., Thomas G. N., Gwilt M., Burger R. A., Higgins A. J. Selective class III antiarrhythmic agents. 1. Bis (arylalkyl) amines. Journal of Medicinal Chemistry 1990; 33: 1151–1155
- Gemmill J. D., Howie C. A., Meredith P. A., Kelman A. W., Rasmussen H. S., Hillis W. S., Elliott H. L. A dose-ranging study of UK-68 798, a novel class III anti-arrhythmic agent, in normal volunteers. British Journal of Clinical Pharmacology 1991; 32: 429–432
- Gillis A. M., Kates R. E. Clinical pharmacokineticts of the newer antiarrhythmic agents. Clinical Pharmocokinetics 1984; 9: 375–403
- Guengerich F. P., Macdonald T. L. Chemical mechanisms of catalysis by cytochrome P-450: a unified view. Accounts of Chemical Research 1984; 17: 9–16
- Gwilt M., Arrowsmith J. E., Blackburn K. J., Burges R. A., Cross P. E., Dalrymple H. W., Higgins A. J. UK-68 798: a novel potent and highly selective antiarrhythmic agent which blocks potassium channels in cardiac cells. Journals of Pharmacology and Experimental Therapeutics 1991; 256: 318–324
- Latini R., Tognoni G., Kates R. E. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics 1984; 9: 136–156
- Sedgewick M., Rasmussen H. S., Walker D., Cobbe S. M. Pharmacokinetics and pharmacodynamic effects of UK-68 798, a new potential class III antiarrhythmic drug. British Journal of Clinical Pharmacology 1991; 31: 515–519
- Smith D. A. Species variations in pharmacokinetics. Drug Metabolism—from Molecules to Man, D. J. Benford, J. W. Bridges, G. G. Gibson. Taylor & Francis, London 1987; 330–351
- Smith D. A., Humphrey M. J., Charuel C. Design of toxicokinetic studies. Xenobiotica 1990; 20: 1187–1199
- Smith D. A. Species differences in metabolism and pharmacokinetics: are we close to an understanding?. Drug Metabolism Reviews 1991; 23: 255–274
- Swabb E. A., Bonner D. P. Prediction of aztreonam pharmacokinetics in humans based on data from animals. Journals of Pharmacokinetics 1983; 11: 215–223
- Vaughan-Williams E. M. Classification of antiarrhythmic drugs. Symposium on Cardiac Arrhythmias, E. Sandoe, E. Flensted-Jensen, K. H. Oleson. AB Astra, Sodertalje 1970; 449–472
- Vozeh S., Schmidlin O., Taeschner W. Pharmacokinetic drug data. Clinical Pharmacokinetics Drug Data Handbook 1989, G. J. Mannem. Adis Press Ltd, Auckland 1989; 1–38
- Walker D. K., Aherne G. W., Arrowsmith J. E., Cross P. E., Kaye B., Smith D. A., Stopher D. A., Wild W. Measurement of the class III antidysrhythmic drug, UK-68 798 in plasma by radioimmunoassay. Journal of Pharmaceutical and Biomedical Analysis 1991a; 9: 141–149
- Walker D. K., Smith D. A., Stopher D. A. Liquid-liquid extraction and high performance chromatography for the determination of a novel antidysrhythmic agent (UK-68 798) in human urine. Journal of Chromatography 1991b; 568: 475–480